Revolutionizing oncology drug development
Presage is at the forefront of changing how novel cancer therapies are developed and promising drug combinations are identified. With Phase 0 microdose trials, evaluation of tumor-based drug activity is now possible earlier than ever before.Discover the benefit of phase 0 microdosing
A bridge between early preclinical experimentation and clinical investigation
Using Presage's patented CIVO® (Comparative In Vivo Oncology) platform, tumor microenvironment response to multiple investigational treatments, alone or in combination, can be observed where it matters most—in a patient's tumor.See how CIVO works
Presage's patented CIVO® (Comparative In Vivo Oncology) technology delivers microdoses of multiple drugs to different regions of a tumor, while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in a naturally occurring tumor has the potential to provide a more detailed understanding of tumor biology, directly encompassing a patient's own immune system, tumor microenvironment, and genetic background. It is Presage’s mission to improve the way that new drugs are developed and targeted, with the goal of ultimately providing more effective treatments to patients with cancer.
Presage collaborates with biopharmaceutical companies to discover new drug combinations and assess novel agents in the most important model of cancer—the human patient.
Questions about how to integrate CIVO into your oncology development strategy?